Table 2. Patient outcomes after neoadjuvant chemotherapy.
| Correlative subseta(n=46) | All(n=65) | |
|---|---|---|
| Overall clinical response (CR+PR)b, n (%) | 37 (80.4) | 53 (81.5) |
| CR | 16 (34.8) | 22 (33.8) |
| PR | 21 (45.7) | 31 (47.7) |
| SD | 5 (10.9) | 7 (10.8) |
| Not determined | 4 (8.7) | 5 (7.7) |
| Surgery, n (%) | 37 (80.4) | 53 (81.5) |
| Pathologic complete response (pCR)c, n (%) | 13 (35.1) | 13 (24.5) |
CR=complete response; PR=partial response; SD=stable disease.
a
Correlative subset includes patients with pretreatment microarray data. Twenty-eight of these patients completed all eight cycles of chemotherapy and had surgery.
b
SWOG overall best study response rates were based on all enroled patients who received at least one dose of chemotherapy. SWOG best response was not determined for patients who discontinued treatment after one or two cycles.
c
The pCR rate was based on the total number of patients who had posttreatment pathology (i.e., 37 for the correlative subset and 53 for all patients).